Corporate ActionJul 8, 2026, 05:31 PM
AEON Biopharma to Raise $11M in Public Offering of Stock & Warrants
AI Summary
AEON Biopharma announced a public offering of 17,479,373 shares of Common Stock, Pre-Funded Warrants, and Milestone Warrants, aiming to raise approximately $11.0 million in net proceeds. The funds are intended for working capital and analytical testing for its ABP-450 biosimilar program. The company disclosed substantial doubt about its ability to continue as a going concern and received a NYSE American non-compliance notice due to a significant stockholders' deficit.
Key Highlights
- Offering 17,479,373 shares of Common Stock at $0.7151 per share.
- Includes Pre-Funded Warrants and Two-Year/Five-Year Milestone Warrants.
- Expected net proceeds of approximately $11.0 million from the offering.
- Proceeds to fund working capital and ABP-450 analytical testing.
- Company faces substantial doubt about its ability to continue as a going concern.
- Received NYSE American non-compliance notice due to stockholders' deficit.
- ABP-450 advancing through FDA 351(k) biosimilar pathway for BOTOX®.
- Analytical studies show 100% amino acid sequence match for ABP-450 to BOTOX®.
Price Impact
More from AEON